A study evaluating efficacy of riociugat as a replacement of sildenafil in patients with inoperable or persistent chronic thromboembolic pulmonary hypertension.

Trial Profile

A study evaluating efficacy of riociugat as a replacement of sildenafil in patients with inoperable or persistent chronic thromboembolic pulmonary hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top